Introduction
Robot-assisted surgery (RAS) was introduced by Cadière in March 1997, when the first telesurgical laparoscopic cholecystectomy was performed. Today, RAS is a reality applied in many surgical specialties.
Conventional laparoscopy (CL) presents several limitations and drawbacks, as limited movements, few degrees of freedom of the tools, inability in performing high-precision dissection and sutures, unnatural positions for surgeon and flat vision. For these reasons, the diffusion of laparoscopy in advanced surgery remains limited to very skilled and experienced surgeons.
Robotic platform (RP) may overcome these technical limits, extending the indications for minimally invasive surgery even in complex procedures, and providing more surgeons able to perform the same ones. However, many issues are still not resolved about RAS, such as effective indications, clinical benefits and long-term oncological results.
The RAS program started at our Institution (Misericordia Hospital, Grosseto, Italy) in October 2000 with Dr. Pier Cristoforo Giulianotti, using the da Vinci Surgical System (Intuitive Surgical Inc., Sunnyvale, CA). From the beginning, RAS offered significant improvements in vision and manipulation inside the corporeal cavities, that is, the idea was that this technological evolution could assist surgeons in complex procedures requiring precise dissection and reconstruction, as in gastric, hepato-pancreato-biliary (HPB) and colorectal oncological surgeries.
We report the current status and a critical review of the applications of RAS in these three specialties, relying on our experience and scientific published literature (Table 1) .
Discussion
In this critical review, the authors have referenced some of their own studies. These referenced studies have been conducted in accordance with the Declaration of Helsinki (1964) and the protocols of these studies have been approved by the relevant ethics committees associated to the institution in which they were performed. All human subjects, in these referenced studies, gave informed consent to participate in these studies.
Robot-assisted gastric surgery
The first experiences of robotassisted gastrectomy (RAG) were published by Giulianotti and Hashizume in 2003 [1] [2] [3] . Afterwards, other reports appeared in published literature, although most included small series and were limited to perioperative outcomes, without data about long-term oncological results.
General Surgery
In the last years, Song and Marano published more consistent series of RAG, including 100 and 236 patients, respectively 4, 5 . Both these studies evaluated perioperative outcomes and oncological adequacy, confirming feasibility and safety of RAG, with radical lymphadenectomy. However, no data were reported about longterm oncological results.
More recently, two reviews 5, 6 and a meta-analysis 7 were published to assess the current status of RAG. Even these papers reported shortterm results, without significant data on long-term survival. Because of this shortfall of studies, the real longterm oncological benefits of RAG remain unclear.
Currently, the accepted indications for RAG are similar to those of CL, that is, RAG should be reserved at T1-T2 tumours, while the robotic approach for advanced gastric cancer (AGC) should be performed only in experienced centres, and in the context of controlled studies. However, most Western authors have reported a variable amount of AGC cases in their series of RAG 8, 9 , and we had a similar experience, that is, about 24% of patients presented an AGC in our unpublished series.
These data induce two important considerations. First, the proportion of AGC cancer in Western countries is higher than in Eastern countries. Second, regardless of the new diagnostic methods, preoperative staging of gastric cancer remains partially ineffective. In our experience, a consistent number of cases were staged as 'advanced' only at post-operative pathological examination. Several authors have reported the risk of under-staging, which can occur in up to 25% of patients diagnosed preoperatively, with early gastric cancer (EGC) [9] [10] [11] [12] . For this reason, some authors have suggested to perform D2-lymphadenectomy as routine practice, even in cases preoperatively staged as EGC 9, 10 . This is also our opinion and part of policy followed in our clinical practice, as well as in many Western institutions.
Based on previous considerations, the importance of technical standardisation of lymphadenectomy is clear. Most surgeons consider D2-lymphadenectomy as the more critical step of minimally invasive gastrectomy for gastric carcinoma. This lymphatic dissection requires a longer learning curve, and it is difficult to reproduce this on a routine basis. This is the main limit for the diffusion of laparoscopic gastrectomy, especially in the Western countries.
Technical advantages offered by RP may help to standardise minimally invasive D2-lymphadenectomy, and to enable surgeons in performing and reproducing this procedure ( Figure 1) 14, 15 . Probably, increased experience and confidence with RP has enabled surgeons to perform high-precision intracorporeal sutures and digestive anastomoses, especially after total gastrectomy.
Technical advantages of RAG (routine reproduction of D2-lymphadenectomy, possibility of enlarged resections and complex reconstructions) could get an important role for RAG, even in therapeutic strategy of AGC, integrating minimally invasive resection with neoadjuvant and adjuvant therapies.
Robot-assisted hepato-pancreatobiliary surgery Liver
Minimally invasive liver resections (LR) are growing worldwide. To date, more than 3000 cases have been published. Knowledge of surgical anatomy, improvements in perioperative care, enhanced imaging modalities, advancement in laparoscopic skills and development of new devices are the main triggers of minimally invasive HPB surgery. In this context, the interest for liver RAS is rising.
Laparoscopic LR has been reported safe in experienced hands, with acceptable morbidity and mortality rates for minor and major hepatectomies 16, 17 . Furthermore, a 5-year survival of patients resected for hepatocellular carcinoma was comparable for laparoscopic and open surgery.
Several specific advantages of minimally invasive LR may be underlined. First, in cirrhotic patients, it has been demonstrated that there is a lower incidence of post-operative ascites after laparoscopic LR, than in open surgery. Second, patients with metastatic liver disease from colorectal cancer may require multiple hepatic and abdominal surgeries in combination with multimodal therapies. In such cases, minimally invasive surgery, if adopted even for LR, can avoid recurrent and enlarged laparotomies.
Some of the following technical steps appear easier and more feasible about the application of RP in liver surgery, from personal experience, than in CL:
• Dissection of the hilum and extraparenchymal approach to hepatic pedicle: This technique can reduce the use of Pringle's manoeuvre during anatomical major hepatectomies, by a selective and preliminary control of hepatic inflow.
• Lymphadenectomy along with hepatic pedicle, common hepatic artery, celiac trunk, and in retropancreatic area, when indicated.
• Exposure and control of the retrohepatic vena cava.
• Access to difficult laparoscopic segments, such as 7, 8 and 4a.
• Bleeding control, even by 'difficult sutures' in 'difficult sites' (Figure 2 ). • Biliary reconstruction and early detection of biliary leaks: This is now enhanced by the use of fluorescence technique.
The major technical limit of liver RAS is the lack of a specific robotic tool dedicated to transect the liver parenchyma, like other tools used in open or laparoscopic surgery that are very efficacious (such as cavitron ultrasonic surgical aspirator). In RAS, the parenchymal transection is carried out by an ultrasound dissector (limited by the lack of Endowrist ® articulation) and bipolar forceps. This method is very precise, but in some cases it results very slowly.
Another drawback is the limitation to perform an intra-operative ultrasound scan by the first surgeon working at the console. During RAS, the intra-operative ultrasound is performed usually by the assistant surgeon at the operating table, using a laparoscopic probe. In difficult situations, this may become a serious drawback for the first surgeon, especially if the assistant surgeon is not experienced with laparoscopic ultrasound. However, this problem seems be resolved by a new generation of "robotic ultrasound probe", which recently appeared in the market. This device is introduced in the abdominal cavity by a port; it is grasped by robotic forceps and is used personally by the first surgeon from the console.
A systematic review on robotassisted LR was published recently by Ho and co-workers 18 and included more than 200 patients. The open conversion rate and morbidity were 4.6% and 20.3 %, respectively despite a possible undervalue, because of selection and publication biases, these data appeared acceptable.
Another paper reported a comparable rate of complications between robot-assisted and laparoscopic LR, concluding that robotic LR was safe and feasible, when performed by experienced surgeons 19 .
A curious report cited a case of laparoscopic LR of segments 7 and 8 that was 'converted' to RAS, because of a stapler malfunction in transecting the right hepatic vein 20 . In this case, Boggi demonstrated the usefulness of RP in controlling major bleeding.
Idrees claimed that several features of the da Vinci robot (three robotic operating arms, articulating tools lockable in place as vascular clamps, and the ability of suturing in difficult situations) were extremely useful in controlling and definitively, managing bleeding without conversion at open surgery 21 . The possibility to lock an articulating tool in place as a vascular clamp could be invaluable, because it gives time for the anaesthesia team to resuscitate the patient, and for the surgical team to formulate a management plan when bleeding complications occur 21 . Although robot-assisted LR appears safe and feasible in experienced hands, long-term oncologic outcomes remain unclear. However, the preliminary short-term results show that RAS is comparable to CL for the treatment of selected liver malignancies.
Pancreas
The current diffusion of laparoscopic pancreatic surgery is limited to easy procedures, as distal pancreatectomy or enucleation. Conversely, laparoscopic pancreatoduodenectomy (LPD) has gained a limited consensus during the years, because of its technical complexity, high rate of conversion and questionable benefits.
In 2003, Giulianotti first reported the robot-assisted pancreatoduodenectomy (RAPD) 1 , and in 2010, he published the larger series of pancreatic RAS performed by a single surgeon 22 . This study included 134 patients (60 RAPD), focusing on technical details and perioperative outcomes. Conversion rate, morbidity and mortality were 10.4%, 26% and 2.23%, respectively. Pancreatic fistula (PF) rate was found to be 31.3% for RAPD and 20.9% for distal pancreatectomy. A redo surgery was performed in four patients (2.9%). 
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Licensee Currently, pancreatoduodenectomy represents more interesting application of robotics in pancreatic surgery, because of its high complexity and technical difficulty. In personal experience, the major advantages offered by RP in this procedure were appreciable in hepatic hilum dissection, lymphadenectomy, uncinate process detachment and reconstruction (biliary and pancreatic anastomoses) (Figure 3 ).
In the last three years, more of 180 RAPDs were reported in the published literature against a more limited number of LPDs reported in the published literature during a larger period of time, to confirm the increasing interest of surgical community in applying robotics in more complex pancreatic surgery.
The open conversion rate of RAPD ranges between 0%-18.3% versus 0%-46% of LPDs 22, 24, 25 . This favourable trend of RAPD is probably because of a better technical standardisation and reproducibility of complex procedures, and to an easier management of difficult steps or intra-operative incidents (as major bleeding), using robotic assistance.
Unfavourable data were reported about the post-operative PF rate, which resulted an apparently upper value for RAPD as compared to the one reported usually for open pancreatoduodenectomy. This may be explained first by the initial learning curve of robotic pancreatic surgeons. Another explanation could be a bias in patients' selection, because in most series, the more frequent indication for RAPD was not the pancreatic ductal carcinoma (tough pancreas, dilated duct), but other pathologies, such as peri-ampullary tumours or benign lesions (usually associated with soft pancreas and small duct). Zeh observed a PF rate of 22% 24 in a series of 50 RAPDs, which included 72% of soft pancreas and 60% of pancreatic duct <3 mm. The incidence of PF was significantly higher in the group of patients with a <3 mm pancreatic duct; furthermore, grade B and grade C fistulas occurred only in this group. These results confirmed that incidence and severity of PF are firstly associated to the anatomical features of pancreas, that is, this is a common problem with open surgery, rather than a specific issue of RAPD.
Other robot-assisted pancreatic procedures were demonstrated to be feasible and safe, as compared to distal and central pancreatectomies, enucleations and decompression of pseudocysts; the interest for these ones is lower than RAPD, because of their feasibility and reproducibility even in CL. However, a particular advantage of RAS seems appreciable in spleen-preserving distal pancreatectomy, a high percentage of success (95%-100%), with preservation and patency of splenic vessels, was reported in a small preliminary series 23, 26 .
Robot-assisted colorectal surgery
In recent years, RAS is assuming greater significance and interest in the treatment of colorectal cancer.
In the last decade, several large randomised studies have shown comparable results between laparoscopic and open surgery, in terms of long-term survival. Nevertheless, technical complexity of laparoscopic total mesorectal excision (TME), long learning curve and other intrinsic drawbacks of CL are considered as the main limits for the diffusion of laparoscopic rectal resection (LRR), especially for restorative low and ultra-low resections.
Till date, LRR remains a challenging procedure with conversion rates as high as 30% 27 . Furthermore, the excellent oncological results of classical randomised trials, comparable with those of open surgery, were obtained by experienced surgeons, in high volume centres, and in selected patients, this is not a warranty to reproduce the same results always and everywhere. Combined with the high rate of conversion, this may explain why LRR is not diffused as expected. Recently, RAS has been claimed in order to make the dissection easier in the narrow pelvis and in obese patients, to reduce the conversion rate and to allow an accurate intersphinteric dissection in case of ultralow resections (Figure 4) .
Other technical advantages of rectal RAS seem to be interesting. First, the ability to perform a purse string on the rectal stump, even in low resections, avoiding the double stapling rectal anastomosis, the single stapling anastomosis can theoretically reduce the rate of leakage. Second, the possibility to treat synchronous rectal cancer and liver metastases, even in difficult cases, as well as hepatic lesions are located in posterior segments or when a major hepatectomy is required.
Several meta-analyses reported comparable results between robotassisted rectal resection (RARR) and LRR, that is, in some cases RARR has shown several advantages versus LRR in the preservation of sexual and urinary functions, especially at shortterm follow-up 28, 29 . The learning curve or RARR was reported shorter than in LRR. For trained surgeons in colorectal laparoscopy, the robotic learning curve is reduced approximately to zero 30 . Although robotic technology seems particularly suitable to improve the minimally invasive TME and to enlarge its diffusion, further studies are required to define its role and its real efficacy in local control of rectal cancer and disease-free survival, in reducing open conversion and post-operative morbidity, and in preserving sexual and urinary functions. These are the goals designed in the worldwide randomised study named Robotic versus Laparoscopic Anterior Rectal Resection (ROLARR), which is still in progress.
For other colonic surgery, RAS does not seem to show significant technical advantages. However, colorectal surgeons can get major ability in helping obese patients, in extended lymphadenectomies for right or transverse colectomy, and for intra-corporeal anastomoses.
Conclusion
Till date, RAS appears to be a growing interest in surgical community. The reported results are satisfactory in terms of conversion rate, blood losses, morbidity and mortality, even for complex surgery as gastric, HPB and rectal procedures.
The technical features of the robotic system can make complex procedures easier and more reproducible, as compared with CL.
A steady three-dimensional view provides excellent resolution, depth perception and magnification. The vision at the console is very similar to that of a surgical microscope and the anatomical details appear to be very clear and precise. Furthermore, technological innovation offers new options, such as fluorescence camera, contemporaneous endoscopic and ultrasound images (Tile Pro), and probably in the future, the possibility of having images in augmented reality.
Wristed instruments enhance the capabilities of dissecting and suturing; this is very important during major oncologic procedures, requiring difficult lymph node dissection and visceral reconstruction.
The fourth robotic arm is used frequently as a stable retractor during surgery. This achieves a prefect exposure of operating field and dissection planes. Furthermore, the surgeon can use the fourth arm like a vascular clamp in order to control major bleeding.
There are two major issues, which are still a burden on RAS. First, the high costs for purchasing the system, yearly maintenance and disposable tools. Second issue is the requirement of an experienced assistant surgeon at the operating table, to perform more complex procedures safely and in better technical conditions. Finally, the results reported in the published literature for RAS are generally limited to technical features, perioperative outcomes and short-term results. More studies will be necessary to evaluate oncological long-term results and to define the better indications and selection of patients for advanced RAS.
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